394 results on '"Puduvalli, Vinay K."'
Search Results
2. Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaCombining Immunotherapy for Glioblastoma
3. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
4. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
5. Triethylammonium salt of a synthesized dicoumarol: Structural insight and human anti-glioblastoma activities
6. Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era
7. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma.
8. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: a retrospective case-control study
9. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.
10. Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastoma
11. Final Report of the Phase II NEXT/CNS-GCT-4 Trial: GemPOx followed by Marrow-ablative Chemotherapy for Recurrent Intracranial Germ Cell Tumors
12. Targeted Therapy for BRAF Mutant Brain Tumors
13. Early imaging marker of progressing glioblastoma: a window of opportunity
14. Current Therapies and Future Directions in Treatment of Glioblastoma
15. Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
16. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
17. Abstract LB127: VAL-083 in patients with recurrent glioblastoma treated under expanded access program
18. Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports
19. Figure S2 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
20. Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
21. Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
22. Supplementary Table 2 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
23. Supplementary Table from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
24. Supplementary Table from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
25. Supplementary Table 1 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
26. Tumor Microenvironment in Glioblastoma: Current and Emerging Concepts
27. A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin
28. BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC.
29. BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P.
30. An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas
31. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience
32. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
33. Epigenetic Changes in Gliomas
34. Chemotherapy of High-Grade Astrocytomas in Adults
35. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
36. Aberrations of the Epigenome in Gliomas: Novel Targets for Therapy
37. Current Therapies and Future Directions in Treatment of Glioblastoma
38. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
39. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms
40. Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey
41. Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
42. Characterization of industry relationships in oncology.
43. Bedside to benchtop translational development: Targeting the S1P/ceramide axis may alleviate symptoms of chemical induced peripheral neuropathy.
44. S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350.
45. A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies.
46. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
47. Inhibition of Angiogenesis as a Therapeutic Strategy against Brain Tumors
48. Proton Beam Craniospinal Irradiation Reduces Acute Toxicity for Adults With Medulloblastoma
49. A multi-resolution textural approach to diagnostic neuropathology reporting
50. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.